Skip to content

Direct comparison of the effects of functionally equivalent dosing regimens of methamphetamine, methcathinone, and α-pyrrolidinopropiophenone on behavioral and neurochemical markers of stimulant-induced neurotoxicity.

Aug 2026 · Behavioural Pharmacology · 0 citations · 47 references
Medicine

TL;DR

All three drug treatments impaired passive avoidance performance, but none caused lasting motor deficits, demonstrating that behavioral deficits can occur without persistent motor changes.

Abstract

Given that previous studies have provided mixed results on cathinone neurotoxicity, we compared the effects of 'functionally equivalent' dosing regimens of methamphetamine (METH), methcathinone, and α-pyrrolidinopropiophenone (α-PPP) on behavioral and neurochemical markers associated with dopaminergic alterations and cognitive function. Male Swiss Webster mice received METH (5 mg/kg), methcathinone (80 mg/kg), or α-PPP (80 mg/kg), using a 'binge'-like dosing regimen (q2h × 4, intraperitoneal). Body weight and temperature were recorded during dosing. Behavior was assessed 2-4 days later, followed by brain extraction. Motor function was evaluated by open-field testing and stride length analysis. Cognitive function was assessed with the passive avoidance test. Striatal levels of dopamine and its major metabolites were measured using ultra-HPLC. All three drug treatments induced weight loss. METH treatment produced a small, transient increase in rectal temperature (~1 °C); methcathinone and α-PPP did not. All three drug treatments impaired passive avoidance performance (P < 0.05 to P < 0.01), but none produced persistent motor deficits. METH and methcathinone treatment significantly reduced striatal dopamine levels (P < 0.001), whereas α-PPP did not, and only METH treatment increased homovanillic acid/dopamine turnover (P < 0.01). Only METH exposure triggered measurable changes in dopamine metabolism and a small, transient increase in temperature, highlighting its distinct neurochemical profile compared with methcathinone and α-PPP under these conditions. All three drug treatments impaired passive avoidance performance, but none caused lasting motor deficits, demonstrating that behavioral deficits can occur without persistent motor changes.

View source

Similar papers

Open access Sep 2026

[Anxiety-like behaviors induced by chronic administration of the synthetic cannabinoid 4F-ABUTINACA in rats and the underlying mechanisms].

OBJECTIVES To elucidate the Δ⁹-tetrahydrocannabinol (THC)-like discriminative stimulus effects of 4F-ABUTINACA and to investigate the potential mechanisms underlying anxiety-like behaviors induced by chronic 4F-ABUTINACA administration. METHODS A THC drug discrimination procedure was used in adult male rats to evalua...

Bao-Bao Shi, Hai-Tao Wang, Wen-Hua Zhou et al. · 0 citations
Open access Aug 2026

European Journal of Pharmacology Neuropharmacological and behavioral characterization of 3F-phenetrazine, a novel amphetamine-like substance, in male mice and rats.

3-Fluorophenetrazine (3F-phenetrazine) is a novel amphetamine-like substance that is structurally similar to phenmetrazine and 3F-phenmetrazine. Despite the emergence of 3F-phenetrazine in recreational drug markets, its neuropharmacological profile and abuse liability remain poorly characterized. This study is the firs...

Su-Min Ban, Kyung Oh Jeon, S. Seo et al. · 0 citations
Open access Aug 2026

Dexmedetomidine attenuates methamphetamine-induced hyperthermia and hyperlocomotion in male rats and modulates monoamine dynamics in the anterior hypothalamus.

RATIONALE Methamphetamine (METH) intoxication is associated with serious complications, including hyperthermia and agitation, which are major contributors to morbidity and mortality. Currently, no established pharmacological interventions are available for these conditions. OBJECTIVES To evaluate the effects of dexme...

Tsuyoshi Okada, Seiji Obi, K. Shioda et al. · 0 citations
Open access Sep 2026

Subchronic Exposure to Low-Dose Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC) Nanoemulsions Suggests Low Renal Toxicity: A Preliminary Study

Background/Objectives: The increasing therapeutic use of cannabinoid-based formulations highlights the need to better characterize their safety profile, particularly in organs involved in xenobiotic elimination, such as the kidneys. This study evaluated the renal effects of cannabidiol (CBD) and Δ9-tetrahydrocannabinol...

Thiago Guedes Pinto, Barbara Dos Anjos Rosario, P. E. D. de Aquino et al. · 0 citations
Open access Sep 2026

Effects of MC-100093, GLT-1 enhancer, in mesolimbic brain regions of C57BL/6 mouse exposed to hydrocodone high-dose challenge using comprehensive laboratory monitoring system

Chronic exposure and overdose of opioid cause neurotoxicity through alterations of several neurotransmitters, including glutamate. Upregulating glutamate transporter 1 (GLT-1) has been shown to attenuate the behavioral and neurochemical effects of chronic exposure to drugs of abuse. This study investigated the effects...

W. Wong, K. K. Bhowmik, W. Childers et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.